Publications

Mondal G, Gonzalez H, Marsh T, Leidal AM, Vlahakis A, Phadatare PR, Bustamante Eguiguren S, Bruck M, Naik A, Magbanua MJM, Huppert LA, Wiita AP, Roose JP, Rosenbluth JM, Debnath J. Autophagy-targeted NBR1-p62/SQSTM1 complexes promote breast cancer metastasis by sequestering ITCH. Nature cell biology. 2025. PMID: 40579454

Hawes MR, Assaf RD, Birkmeyer JA, Philbin MM, Vijayaraghavan M, Kushel M. Tobacco Use Patterns and Missed Opportunities for Cessation Treatment Among People Experiencing Homelessness. Journal of general internal medicine. 2025. PMID: 40562886

Farhan S, Kennedy VE, Espinoza-Gutarra MR, Lust H, Bobillo MSO, Lin AY, Olin RL, Lin RJ, Rentscher KE, Taylor MR, Mohanraj L, Wood WA, Murthy HS, Ahmed N, Dueck AC, Phelan R, Kelly DL, Yuen C, Munshi PN, Schoemans H, Hamilton BK, Lee C, Sung AD. Assessing physical function in transplantation and CAR-T recipients: expert recommendations from the survivorship, aging and biobehavioral special interest groups of ASTCT. Transplantation and cellular therapy. 2025. PMID: 40545000

Yang H, Song H, Yip E, Gilpatrick T, Chang K, Allegakoen P, Lu KL, Hui K, Pham JH, Kasap C, Kumar V, Gayle J, Stohr BA, Cornelia Ding CK, Wiita AP, Meng MV, Chou J, Porten SP, Huang FW. Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression. Nature communications. 2025. PMID: 40527915

H. Geng, M. Randall, A. Ballapuram, L. Chen, C. Yung, M. Lu, C. Lowell, J. L. Rubenstein. THE TOLL-LIKE RECEPTOR 7/8 PATHWAY HAS PROGNOSTIC SIGNIFICANCE AND IS A THERAPEUTIC TARGET IN CNS LYMPHOMAS. Hematological Oncology. 2025. PMID:

D. A. Solomon, H. Geng, M. Randall, R. Sobel, J. Cleveland, A. Ballapuram, L. Chen, M. Lu, S. Cha, C. Lowell, W. P. Devine, J. L. Rubenstein. THERAPY-DRIVEN EVOLUTION AND INTRATUMORAL GENETIC HETEROGENEITY IN CNS LYMPHOMAS. Hematological Oncology. 2025. PMID:

Najjar YG, Orloff M, Mitchell TC, Bowles TL, Betof Warner A, Bollin K, Chandra S, Cohen JV, Eroglu Z, Funchain P, Gaughan E, Glitza Oliva I, Hsu S, Hu-Lieskovan S, Kennedy LB, Truong TG, McKean M, Mehnert J, Moon H, Tsai KK, Wilson M, Tran T, Buchbinder EI, Fecher LA, Guild S, Patel SP. Proceedings of the seventh annual Women in Melanoma Conference. Therapeutic advances in medical oncology. 2025. PMID: 40535733

Laura A. Huppert, Kelsey Kuwahara, Maggie Zhou, Mia Salans, Samantha Fisch, Jo Chien, Melanie Majure, Hope Rugo, Lauren Boreta, Steve E. Braunstein, Ramin A. Morshed, Harish N. Vasudevan, Michelle E. Melisko. Abstract P5-10-01: Demographic, Clinical Characteristics, and Overall Survival of Patients with Metastatic Breast Cancer and Brain Metastases: A Single Center Retrospective Cohort Study. Clinical Cancer Research. 2025. PMID:

Samantha Fisch, Joshua Chin, Laura Quintal, Melanie Majure, Michelle Melisko, Jo Chien, Hope S. Rugo, Laura A. Huppert. Abstract P5-12-25: Single-center retrospective cohort study evaluating neutropenia and growth factor use with sacituzumab govitecan in patients with HR+/HER2- and triple negative metastatic breast cancer. Clinical Cancer Research. 2025. PMID:

Alexis LeVee, Saya Jacob, Samantha Fisch, Carolyne Face, Madhuri Chengappa, Saliha Chaudhry, Nikita Baclig, Andrew Soliman, Nora Ruel, Megan Wong, Karen Tsai, Irene Kang, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Melissa Lechner, Dame Idossa, Anne Blaes, Kelly McCann, Hope S. Rugo, Joanne Mortimer. Abstract PS5-03: Incidence and Risk Factors of Immune-Related Adverse Events in Early-Stage Breast Cancer Patients: Findings from a Multi-Institutional Study. Clinical Cancer Research. 2025. PMID:

Nikita Baclig, Andrew Soliman, Saya Jacob, Alexis LeVee, Samantha Fisch, Carolyn Face, Madhuri Chengappa, Saliha Chaudhry, Dame Idossa, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Joanne Mortimer, Anne Blaes, Hope S. Rugo, Melissa Lechner, Kelly E. McCann. Abstract P1-04-07: Incidence and Risk Factors of Immune-Related Adverse Events in Metastatic Breast Cancer Patients: Findings from a Multi-Institutional Study. Clinical Cancer Research. 2025. PMID:

Madhuri Chengappa, Thejaswi K Poonacha, Nikitha Vobugari, Go Nishikawa, Saya Jacob, Samantha Fisch, Carolyn Face, Alexis LeVee, Nikita V. Baclig, Andrew Soliman, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Joanne Mortimer, Kelly McCann, Hope S. Rugo, Dame Idossa, Anne Blaes. Abstract P1-12-04: Correlation between Immune-Related Adverse Events (irAE) and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Immune Checkpoint Inhibitors (ICI): a multi-institutional study. Clinical Cancer Research. 2025. PMID:

Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, Madanat YF, Swords R, Baer MR, Blum W, Stein EM, Olin RL, Schiller G, Nichols A, Odenike O, Traer E, Lachowiez C, Duong VH, Hochman MJ, Cai SF, Smith C, Stefanos M, Martycz M, Huang Y, Rosenberg L, Marcus S, Chen TL, Yocum AO, Druker BJ, Levine RL, Borate U, Byrd JC, Mims AS. Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40504618

Tien JC, Zhai Y, Wu R, Zhang Y, Chang Y, Cheng Y, Todd AJ, Wheeler CE, Li S, Mannan R, Cheng C, Magnuson B, Cruz G, Cao Y, Mahapatra S, Stolfi C, Cao X, Su F, Wang R, Yang J, Zhou L, Qiao Y, Xiao L, Cieslik M, Wang X, Wang Z, Chou J, Fearon ER, Ding K, Cho KR, Chinnaiyan AM. Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2025. PMID: 40504161

Zhou P, Mansukhani MM, Yeh R, Lu J, Xia H, Koganti L, Pang J, Toskic D, Scalia S, Ma X, Lee LX, Wong SW, Chung A, Tuchman SA, Fogaren T, Coady Lyons N, Varga C, Lentzsch S, Comenzo RL. Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies. Journal of clinical medicine. 2025. PMID: 40565890

Miller J, Cuby J, Hall SM, Stitzer M, Kushel M, Appiah D, Vijayaraghavan M. Corrigendum to "Tobacco use behaviors and views on engaging in clinical trials for tobacco cessation among individuals who experience homelessness" [Contemporary Clinic. Trials Commun. 32 (2023) 101094]. Contemporary Clinical Trials Communications. 2025. PMID: 40727927

Liao N, Li C, Gradishar WJ, Klimberg VS, Roshal JA, Yuan T, Agarwala SS, Valero VK, Swain SM, Margenthaler JA, Rubio IT, Hurvitz SA, Geyer CE, Lin NU, Rugo HS, Zhang G, Liu N, Balch CM. Accuracy and Reproducibility of ChatGPT Responses to Breast Cancer Tumor Board Patients. JCO clinical cancer informatics. 2025. PMID: 40466030

Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM. Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40459151

Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW, Jiang D, Gammon ST, Willey CD, Boutros PC, Sandulache VC, Osman AA, Myers JN, Mehla K, Singh PK, Chan KS, Gao H, Marathe H, National Cancer Institute (NCI) Acquired Resistance to Therapy Network (ARTNet). Acquired resistance in cancer: towards targeted therapeutic strategies. Nature reviews. Cancer. 2025. PMID: 40461793

Jonas BA, Fisch SC, Curtin PT, Schiller GJ, Jeyakumar D, Tzachanis D, Bejar R, Qi L, Wieduwilt MJ, Tuscano JM, Damon L, Logan AC, University of California Hematologic Malignancies Consortium. A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). Leukemia Research. 2025. PMID: 40479857